CD22 and acute lymphoblastic leukemia: On 6 March 2024, the U.S. Food and Drug Administration granted approval for the use of InO (Besponsa, Pfizer) in pediatric patients aged 1 year or older with R/R CD22-positive BCP-ALL [164].